PortViewPortView
Applied DNA Sciences logo

Applied DNA Sciences (APDN) Stock Analysis

NASDAQHealthcareMedical - Diagnostics & Research

$5.62+31.62%
1-year price historyRange $2.32 – $185.25
52-week range$5.62
$2.13$319.95

What Applied DNA Sciences does

Applied DNA Sciences, Inc. specializes in devising and marketing sophisticated DNA-centric technological solutions across diverse sectors. Its activities encompass nucleic acid-based in vitro diagnostics and the preclinical development and production of nucleic acid-based pharmaceuticals. Furthermore, the company offers robust solutions for bolstering supply chain security, combating counterfeiting, and preventing theft. Key offerings for product authenticity and supply chain integrity include SigNature molecular tags, which imbue products with forensic traceability and protection, thereby strengthening brand defense and supply chain resilience while aiding in criminal identification and prosecution. To facilitate real-time, field-based verification of these tags, they provide SigNify IF portable DNA readers along with corresponding SigNify consumable reagent test kits. The CertainT platform represents a holistic approach, integrating tagging, testing, and tracking capabilities, empowering manufacturers, brands, and trade organizations to substantiate their product claims with verifiable evidence. Within the diagnostic realm, the company produces the LineaTM COVID-19 Assay Kit, a PCR-based molecular diagnostic test. It also offers the safeCircle COVID-19 diagnostic kit, specifically designed to help curtail viral transmission within communal settings such as schools or workplaces. Additionally, Applied DNA Sciences delivers contract research and manufacturing services for the burgeoning nucleic acid-based therapeutic markets during their preclinical phases. This extends to providing contract research for clients involved in preclinical studies of RNA-based drugs and biologics. The company is also at the forefront of developing an innovative technology for the capture and identification of invasive circulating tumor cells, utilizing a proprietary functional assay to isolate live invasive tumor cells and their associated lymphocytes. Operating internationally, the firm maintains a significant footprint across the United States, Europe, and Asia. Founded in 1983, the organization was initially known as Datalink Systems, Inc., before officially changing its name to Applied DNA Sciences, Inc. in 2002. Its corporate headquarters are located in Stony Brook, New York.

Key metrics

Market cap
$7.26M
P/E (TTM)
-0.10
EPS (TTM)
$-57.12
Beta
0.13
Dividend yield
0.00%
Revenue / share
$0.22
50-day avg
$3.55
200-day avg
$35.61
52-week high
$319.95
52-week low
$2.13
CEO
James A. Hayward Sc.D.

ETFs linked to APDN

Broad-market and Healthcare sector ETFs an investor holding Applied DNA Sciences is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how APDN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze APDN in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Applied DNA Sciences?
Applied DNA Sciences trades under the ticker APDN on NASDAQ.
Which exchange is APDN listed on?
APDN is listed on NASDAQ.
What sector does Applied DNA Sciences operate in?
Applied DNA Sciences is classified in the Healthcare sector (Medical - Diagnostics & Research industry).
How can PortView help analyze APDN in a portfolio?
PortView shows APDN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.